Innovent Biologics Inc/ADR
IVBXFDrugs in Pipeline
43
Phase 3 Programs
20
Upcoming Catalysts
10
Next Catalyst
This month
Market Overview
Stock performance and key metrics
10 upcoming, 1 past
IBI302 8mg dose Phase 2 Est. Readout
Estimated primary completion for IBI302 8mg dose trial (NCT07275840) in Neovascular Age-related Macular Degeneration. Topline data typically follows completion by weeks to months.
SourceIBI306 Phase 3 Est. Readout
Estimated primary completion for IBI306 trial (NCT07473960) in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia. Topline data typically follows completion by weeks to months.
Source8 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
IBI306
Homozygous Familial Hypercholesterolemia
IBI311
Thyroid Eye Disease
IBI354
Locally Advanced Unresectable or Metastatic Solid Tumors
IBI303
AS
IBI301 plus CHOP
Diffuse, Large B-Cell, Lymphoma
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
IBI308
Esophageal Squamous Cell Carcinoma
paclitaxel/Gemcitabine/Liposomal doxorubicin
Ovarian
Platinum
Lung Neoplasms
IBI310
Advanced Cervical Cancer
IBI305
Non-Squamous Non-Small Cell Lung Cancer
IBI343
Pancreatic Cancer
IBI112
Psoriasis
Febuxostat
Gout
Sintilimab
Esophageal Squamous Cell Carcinoma
IBI305 in Combination with Paclitaxel/Carboplatin
NSCLC
IBI362
Type 2 Diabetes
IBI310&Sintilimab
MSI-H
IBI306 450mg SC Q4W
Hypercholesterolemia
Picankibart
Plaque Psoriasis
IBI302
Diabetic Macular Oedema
dose 1 IBI302
Neovascular Age-related Macular Degeneration
Period 2 IBI112 dose 3
Ulcerative Colitis (UC)
GFH925
KRAS G12C
IBI311 (20 mg)
Thyroid Eye Disease
Low dose IBI302
Neovascular Age-related Macular Degeneration
IBI3003
Multiple Myeloma
IBI112 dose 2
Psoriasis
PD1
Relapsed/Refractory Classical Hodgkin's Lymphoma
IBI376
Indolent Non-hodgkin Lymphoma
IBI363
Melanoma
IBI334
Advanced Solid Tumors
IBI130
Solid Tumor
IBI129
Solid Tumor
IBI343,sintilimab,oxaliplatin,S-1
CLDN18.2 Positive
IBI302 8mg dose
Neovascular Age-related Macular Degeneration
regular treatment
Psoriasis
IBI343,Gemcitabine, Albumin-bound Paclitaxel
CLDN18.2 Positive
IBI128
Gout
Pemigatinib
Cholangiocarcinoma
IBI3014
Unresectable Locally Advanced or Metastatic Solid Tumors
IBI133
Locally Advanced Unresectable or Metastatic Solid Tumors
IBI3002
Atopic Dermatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IBI306 | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
IBI311 | Phase 3 | Thyroid Eye Disease | - | - |
IBI354 | Phase 3 | Locally Advanced Unresectable or Metastatic Solid Tumors | - | - |
IBI303 | Phase 3 | AS | - | - |
IBI301 plus CHOP | Phase 3 | Diffuse, Large B-Cell, Lymphoma | - | - |
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI） | Phase 3 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | - | - |
IBI308 | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
paclitaxel/Gemcitabine/Liposomal doxorubicin | Phase 3 | Ovarian | - | - |
Platinum | Phase 3 | Lung Neoplasms | - | - |
IBI310 | Phase 3 | Advanced Cervical Cancer | - | - |
IBI305 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
IBI343 | Phase 3 | Pancreatic Cancer | - | - |
IBI112 | Phase 3 | Psoriasis | - | - |
Febuxostat | Phase 3 | Gout | - | - |
Sintilimab | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
IBI305 in Combination with Paclitaxel/Carboplatin | Phase 3 | NSCLC | - | - |
IBI362 | Phase 3 | Type 2 Diabetes | - | - |
IBI310&Sintilimab | Phase 3 | MSI-H | - | - |
IBI306 450mg SC Q4W | Phase 3 | Hypercholesterolemia | - | - |
Picankibart | Phase 3 | Plaque Psoriasis | - | - |
IBI302 | Phase 2 | Diabetic Macular Oedema | - | - |
dose 1 IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
Period 2 IBI112 dose 3 | Phase 2 | Ulcerative Colitis (UC) | - | - |
GFH925 | Phase 2 | KRAS G12C | - | - |
IBI311 (20 mg) | Phase 2 | Thyroid Eye Disease | - | - |
Low dose IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
IBI3003 | Phase 2 | Multiple Myeloma | - | - |
IBI112 dose 2 | Phase 2 | Psoriasis | - | - |
PD1 | Phase 2 | Relapsed/Refractory Classical Hodgkin's Lymphoma | - | - |
IBI376 | Phase 2 | Indolent Non-hodgkin Lymphoma | - | - |
IBI363 | Phase 2 | Melanoma | - | - |
IBI334 | Phase 2 | Advanced Solid Tumors | - | - |
IBI130 | Phase 2 | Solid Tumor | - | - |
IBI129 | Phase 2 | Solid Tumor | - | - |
IBI343,sintilimab,oxaliplatin,S-1 | Phase 2 | CLDN18.2 Positive | - | - |
IBI302 8mg dose | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
regular treatment | Phase 2 | Psoriasis | - | - |
IBI343,Gemcitabine, Albumin-bound Paclitaxel | Phase 2 | CLDN18.2 Positive | - | - |
IBI128 | Phase 2 | Gout | - | - |
Pemigatinib | Phase 2 | Cholangiocarcinoma | - | - |
IBI3014 | Phase 2 | Unresectable Locally Advanced or Metastatic Solid Tumors | - | - |
IBI133 | Phase 2 | Locally Advanced Unresectable or Metastatic Solid Tumors | - | - |
IBI3002 | Phase 2 | Atopic Dermatitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Innovent Biologics Inc/ADR's drug pipeline?→
CatalystAlert tracks 43 drug candidates in Innovent Biologics Inc/ADR's (IVBXF) pipeline across Phase 3, Phase 2. Its lead program is IBI306 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Innovent Biologics Inc/ADR's next FDA catalyst?→
Innovent Biologics Inc/ADR's (IVBXF) next tracked catalyst is a Phase 2 expected August 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IVBXF biotech catalysts?→
Add IVBXF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Innovent Biologics Inc/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.